Amgen (AMGN) was steady earlier in Tuesday’s late session after the biotech company tonight said a new analysis of its Repatha medication showed lowering low-density lipoprotein cholesterol levels reduced the risk of cardiovascular events in a sub-group of patients with a history of stroke who were participating in a clinical trial of the drug.
According to the company, the clinical benefit for potential stroke patients has not been reported before. The study found that 19% of 27,564 patients in a late-stage study of Repatha had a prior history of non-hemorrhagic stroke and that among that group of patients, they experienced a 56% mean reduction in LDL cholesterol levels compared with patients in the placebo group.
The study “unequivocally showed that lowering LDL-C with Repatha results in a powerful risk reduction for patients at high risk of a cardiovascular event,” said Dr. Sean Harper, executive vice president for research and development at Amgen.
Separately, Amgen tonight also said results from a late-stage coronary intravascular ultrasound imaging trial found that while virtual histology showed an increase in dense calcium in the coronary artery plague as well as a reduction in LDL cholesterol in patients treated with either Rapatha or a statin anti-cholesterol medication. The sub-study also showed reductions in LDL-C and atheroma volume was consistent with the results of the larger trial population.
Data from both studies were presented at the European Society of Cardiology Congress in Barcelona, Spain.